DRUG
Bright Minds Biosciences Inc
NASDAQ: DRUG · HEALTHCARE · BIOTECHNOLOGY
$89.11
+0.13% today
Updated 2026-04-29
Market cap
$872.62M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.02
Dividend yield
—
52W range
$23 – $124
Volume
0.2M
Bright Minds Biosciences Inc (DRUG) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+21.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-9800.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+1.0%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+2.0%
2025-12-23
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-12 | $-0.97 | +18.1% | $77.92 | $77.90 | -0.0% |
| 2025-12-23 | $-0.57 | +42.9% | $83.01 | $84.66 | +2.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-1.19 | $-0.97 | +18.1% | — | — |
| 2025-09-30 | $-1.00 | $-0.57 | +42.9% | — | — |
| 2025-06-30 | $-0.88 | $-0.74 | +16.1% | — | — |
| 2025-03-31 | $-0.46 | $-0.42 | +8.7% | — | — |
| 2024-12-31 | $-0.50 | $0.01 | +102.0% | — | — |
| 2024-09-30 | $-0.60 | $-0.17 | +71.7% | — | — |
| 2024-06-30 | — | $0.04 | — | — | — |
| 2024-03-31 | — | $-0.10 | — | — | — |
| 2023-12-31 | — | $-0.32 | — | — | — |
| 2023-09-30 | — | $-0.30 | — | — | — |
| 2023-06-30 | $0.00 | $-0.29 | — | — | — |
| 2023-03-31 | $0.00 | $-0.08 | — | — | — |
Frequently asked questions
Has Bright Minds Biosciences Inc beaten earnings estimates?
Bright Minds Biosciences Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +21.4% over the last 4 quarters.
How does DRUG stock react to earnings?
DRUG stock has moved an average of +1.0% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.